These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21890778)

  • 21. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
    Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J; Heera J; Mayer H
    HIV Clin Trials; 2010; 11(3):125-32. PubMed ID: 20736149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
    Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
    Rodriguez C; Soulié C; Marcelin AG; Calvez V; Descamps D; Charpentier C; Flandre P; Recordon-Pinson P; Bellecave P; Pawlotsky JM; Masquelier B;
    PLoS One; 2015; 10(6):e0127816. PubMed ID: 26068869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virological failure of patients on maraviroc-based antiretroviral therapy.
    Raymond S; Maillard A; Amiel C; Peytavin G; Trabaud MA; Desbois D; Bellecave P; Delaugerre C; Soulie C; Marcelin AG; Descamps D; Izopet J;
    J Antimicrob Chemother; 2015; 70(6):1858-64. PubMed ID: 25700719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
    Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
    AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.
    Thielen A; Lengauer T; Swenson LC; Dong WW; McGovern RA; Lewis M; James I; Heera J; Valdez H; Harrigan PR
    Antivir Ther; 2011; 16(3):319-28. PubMed ID: 21555814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.
    Weber J; Vazquez AC; Winner D; Gibson RM; Rhea AM; Rose JD; Wylie D; Henry K; Wright A; King K; Archer J; Poveda E; Soriano V; Robertson DL; Olivo PD; Arts EJ; Quiñones-Mateu ME
    J Clin Microbiol; 2013 May; 51(5):1517-27. PubMed ID: 23486708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordance rates between Trofile test and short-term virological response to maraviroc.
    Genebat M; Ruiz-Mateos E; González-Serna A; Pulido I; Muñoz-Fernández MÁ; Ferrando-Martínez S; Leal M
    Antiviral Res; 2011 Feb; 89(2):182-5. PubMed ID: 21134404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Next generation sequencing reveals a high frequency of CXCR4 utilizing viruses in HIV-1 chronically infected drug experienced individuals in South Africa.
    Matume ND; Tebit DM; Gray LR; Hammarskjold ML; Rekosh D; Bessong PO
    J Clin Virol; 2018 Jun; 103():81-87. PubMed ID: 29661652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
    Genebat M; Ruiz-Mateos E; León JA; González-Serna A; Pulido I; Rivas I; Ferrando-Martínez S; Sánchez B; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Oct; 64(4):845-9. PubMed ID: 19671585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial.
    Charpentier C; Joly V; Larrouy L; Fagard C; Visseaux B; de Verdière NC; Raffi F; Yeni P; Descamps D;
    J Antimicrob Chemother; 2013 Mar; 68(3):690-6. PubMed ID: 23152480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
    Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
    J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
    Genebat M; de Pablo-Bernal RS; Pulido I; Jiménez-Mejías ME; Martínez O; Pacheco YM; Raffi-El-Idrissi Benhia M; Abad MA; Ruiz-Mateos E; Leal M
    Antiviral Res; 2015 Sep; 121():94-6. PubMed ID: 26122170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.
    Archer J; Weber J; Henry K; Winner D; Gibson R; Lee L; Paxinos E; Arts EJ; Robertson DL; Mimms L; Quiñones-Mateu ME
    PLoS One; 2012; 7(11):e49602. PubMed ID: 23166726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
    McNicholas P; Vilchez RA; Greaves W; Kumar S; Onyebuchi C; Black T; Strizki JM
    J Clin Virol; 2012 Oct; 55(2):134-9. PubMed ID: 22824230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Methods for determination of HIV tropism and their clinical use].
    Gutiérrez F; Rodríguez JC; García F; Poveda E
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():45-50. PubMed ID: 22305669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.